Streetbeat News

Stock Prices

RWT

Over the past 3 months, 4 Wall Street analysts have provided ratings for Redwood Trust (NYSE:RWT), with 3 being bullish and 1 somewhat bullish. There have been no bearish or somewhat bearish ratings. The average 12-month price target among these analysts is $8.88, which is a 1.33% decrease from the previous target of $9.00. The ratings suggest a positive outlook for RWT stock.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 3:00 pm

PL

Planet Labs (NYSE:PL) is scheduled to release its quarterly earnings report on Thursday, 2023-12-07, with an expected EPS of $-0.08. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, the company's stock price has been sensitive to earnings performance and guidance. Last quarter, PL missed EPS estimates by $0.06, resulting in an 11.04% share price drop the following day. Over the last year, PL shares have declined by 51.4%.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 3:00 pm

SOLUSD

Solana's (CRYPTO: SOL) price has increased by 3.81% in the last 24 hours, reaching $62.8, continuing a positive trend with a 4.0% gain over the past week. The coin's all-time high is $259.96. Trading volume for Solana has surged by 90.0% over the past week, and the circulating supply has risen by 0.43%, now at 425.47 million. Solana's market cap is currently ranked #6, valued at $26.76 billion.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 3:00 pm

LQDT

Liquidity Services (NASDAQ:LQDT) is scheduled to release its quarterly earnings report on Thursday, 2023-12-07, with analysts expecting an EPS of $0.00. Investors are looking for an earnings beat and positive guidance for future growth. Historically, the company's stock price has shown mixed reactions to past earnings results. Shares are currently trading at $19.59, up 38.62% over the last 52 weeks, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 3:00 pm

CRSP

CRISPR Therapeutics (NASDAQ:CRSP) has delivered an average annual return of 14.74% over the past 5 years, outperforming the market by 3.11% on an annualized basis. A $1000 investment in CRSP 5 years ago would now be worth $2,011.90. The company's current market capitalization stands at $5.66 billion.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 3:00 pm

DOTUSD

Polkadot's (CRYPTO: DOT) price has seen a significant increase of 10.23% in the past 24 hours, reaching $6.13. Over the last week, DOT has gained 16.0%, rising from $5.25. Despite the recent surge, it is still far from its all-time high of $54.98. The trading volume has increased by 110.0% over the past week, while the circulating supply slightly decreased by 0.02%, now standing at 1.30 billion. Polkadot's market cap is currently ranked #14, valued at $8.00 billion.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 3:00 pm

DOGEUSD

Dogecoin (CRYPTO: DOGE) has seen a significant increase of 13.89% in the past 24 hours, reaching a price of $0.10. Over the last week, DOGE has gained 27.0%, rising from $0.08. Despite the recent surge, it is still below its all-time high of $0.73. Trading volume has increased by 269.0%, while the circulating supply has slightly decreased by 0.36%, with a current market cap ranking of #10 at $14.49 billion.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 3:00 pm

DVN

JP Morgan analyst Arun Jayaram has upgraded Devon Energy (NYSE:DVN) from Neutral to Overweight and increased the price target from $57 to $58. This reflects a positive outlook on the company's stock by the analyst.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 2:57 pm

GRFX

Graphex Group Limited has received a preliminary offer from a NASDAQ-listed blank check company to acquire its subsidiary, Graphex Technologies, for $100M-$200M in stock. The acquisition aims to make Graphex Tech an independent U.S. company serving the Li-ion battery anode material market in North America. The deal is subject to shareholder approval, registration of shares, and compliance with regulatory bodies. The transaction is expected to close in the first half of 2024, with Graphex Group distributing shares to its shareholders post-acquisition. CEO John DeMaio will continue to lead Graphex Tech, which is positioning itself as a key player in the EV battery supply chain amid graphite export restrictions from China.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 2:56 pm

NVO

A study analyzing medical records and insurance claims data showed that 40% of patients prescribed Novo Nordisk's obesity drug Wegovy were still using it after a year, indicating higher adherence compared to older medications. The study, published in Obesity, involved 1,911 adults and found that greater weight loss at six months predicted continued use at one year. In contrast, only 13% and 10% of patients remained on Orexigen Therapeutics' Contrave and Vivus's Qsymia, respectively, after a year. The study did not explore why patients stopped taking the drugs but noted insurance coverage and pre-certification criteria as factors affecting adherence. Dr. Hamlet Gasoyan raised concerns about the cost of new anti-obesity drugs and their impact on insurance coverage decisions. Novo Nordisk's stock (NYSE:NVO) was down 0.94% at $98.69.

Portfolio Pulse from Vandana Singh

December 06, 2023 | 2:53 pm